Literature DB >> 22858451

Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases.

Jae-Hoon Kim1, Soo-Kyung Cho, Minkyung Han, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Sang-Cheol Bae, Dae-Hyun Yoo, Yoon-Kyoung Sung.   

Abstract

OBJECTIVES: To estimate the positivity and agreement between QuantiFERON-tuberculosis (TB) gold in tube test (QFT-GIT) and tuberculin skin test (TST) according to underlying rheumatic diseases and to identify the influencing factors on discrepancies between the 2 tests.
METHODS: Among the 757 patients who underwent both QFT-GIT and TST simultaneously from September 2008 to November 2010, patients with indeterminate QFT-GIT results (n = 21), with active (n = 11) or suspicious (n = 1) findings for tuberculosis on a chest radiograph, were excluded. Finally, 724 patients were recruited for this study: 497 patients with rheumatoid arthritis (RA), 198 with ankylosing spondylitis (AS), and 29 with juvenile rheumatoid arthritis (JRA). The agreement between the 2 tests was estimated by Cohen's κ and factors influencing discrepancies were identified using multivariate analysis.
RESULTS: The positivity of QFT-GIT was higher in RA than AS or JRA (30.2%, 16.2%, and 3.4%, respectively). In contrast, TST positivity was highest in AS compared to RA and JRA (45.5%, 28.2%, and 17.2%, respectively). The agreement between the 2 tests was low in all patients (κ = 0.285). The only predictor of a discrepancy between the 2 tests was older age. Factors associated with discordant QFT-GIT-negative/TST-positive results were female [odds ratio (OR) = 2.33, confidence interval (CI) 1.11 to 4.89] and AS (OR = 3.12, CI 1.44 to 6.79), whereas a discordant QFT-GIT-positive/TST-negative result was associated with glucocorticoid use (OR = 2.44, CI 1.24 to 4.81).
CONCLUSIONS: The agreement between the 2 tests is low; therefore, it would be better to perform both tests than to use any 1 test alone for the detection of LTBI in TB-endemic regions. Female and underlying AS are related to being QFT-GIT-negative/TST-positive, and the use of glucocorticoid is associated with being QFT-GIT-positive/TST-negative.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22858451     DOI: 10.1016/j.semarthrit.2012.07.001

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  13 in total

1.  Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.

Authors:  Giovana Garziera; André Luis Bittencourt Morsch; Felipe Otesbelgue; Fernanda Luiza Staub; Penélope Esther Palominos; Claiton Viegas Brenol; Denise Rossato Silva
Journal:  Clin Rheumatol       Date:  2017-06-06       Impact factor: 2.980

Review 2.  Infection Risk and Safety of Corticosteroid Use.

Authors:  Jameel Youssef; Shannon A Novosad; Kevin L Winthrop
Journal:  Rheum Dis Clin North Am       Date:  2015-10-24       Impact factor: 2.670

3.  Screening Optimization of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients.

Authors:  Bella Mehta; Ekaterini Zapantis; Olga Petryna; Petros Efthimiou
Journal:  Arthritis       Date:  2015-07-29

4.  Follow-up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infection.

Authors:  Chang-Nam Son; Jae-Bum Jun; Jong-Heon Kim; Il-Hoon Sung; Dae-Hyun Yoo; Tae-Hwan Kim
Journal:  J Korean Med Sci       Date:  2014-07-30       Impact factor: 2.153

5.  QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.

Authors:  Hyun Lee; Hye Yun Park; Kyeongman Jeon; Byeong-Ho Jeong; Ji-Won Hwang; Jaejoon Lee; Hoon-Suk Cha; Eun-Mi Koh; Eun-Suk Kang; Won-Jung Koh
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

6.  Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis.

Authors:  Tan N Doan; Damon P Eisen; Morgan T Rose; Andrew Slack; Grace Stearnes; Emma S McBryde
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

7.  Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy.

Authors:  Yoon-Kyoung Sung; Soo-Kyung Cho; Dam Kim; Soyoung Won; Chan-Bum Choi; Tae-Hwan Kim; Jae-Bum Jun; Dae-Hyun Yoo; Sang-Cheol Bae
Journal:  Korean J Intern Med       Date:  2017-03-13       Impact factor: 2.884

8.  Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases.

Authors:  Junhee Pyo; Soo-Kyung Cho; Dam Kim; Yoon-Kyoung Sung
Journal:  Korean J Intern Med       Date:  2017-12-28       Impact factor: 2.884

9.  Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting.

Authors:  Padmapriyadarsini Chandrasekaran; Vidya Mave; Kannan Thiruvengadam; Nikhil Gupte; Shri Vijay Bala Yogendra Shivakumar; Luke Elizabeth Hanna; Vandana Kulkarni; Dileep Kadam; Kavitha Dhanasekaran; Mandar Paradkar; Beena Thomas; Rewa Kohli; Chandrakumar Dolla; Renu Bharadwaj; Gomathi Narayan Sivaramakrishnan; Neeta Pradhan; Akshay Gupte; Lakshmi Murali; Chhaya Valvi; Soumya Swaminathan; Amita Gupta
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

10.  Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high-burden setting.

Authors:  Jyoti S Mathad; Ramesh Bhosale; Vikrant Sangar; Vidya Mave; Nikhil Gupte; Savita Kanade; Ashwini Nangude; Kavita Chopade; Nishi Suryavanshi; Prasad Deshpande; Vandana Kulkarni; Marshall J Glesby; Daniel Fitzgerald; Renu Bharadwaj; Pradeep Sambarey; Amita Gupta
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.